Lydall Company Overview, Contact Details & Competitors

Insights

Gathering insights about Lydall…

Similar companies to Lydall

Lydall Tech Stack

Lydall uses 8 technology products and services including Microsoft SharePoint, Oracle, Pure Storage, and more. Explore Lydall's tech stack below.

Microsoft SharePoint
Content Management System
Oracle
Enterprise
Pure Storage
Enterprise Data Storage
Covisint
IT Infrastructure
Windows Server
Operating Systems
Microsoft Azure
Platform As A Service
VMware
Virtualisation Software
Apache HTTP Server
Web Servers

Media & News

Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9
Single infusion of VERVE-102 led to dose-dependent decreases in blood PCSK9 and LDL-C, with mean reduction in LDL-C of 53% and a maximum reduction of 69% observed in the 0.6 mg/kg dose cohort
Apr 14, 2025 | www.globenewswire.com
LDLC: heavier first-half losses
LDLC announced on Friday that it had increased its losses in the first half of the year, explaining that the unfavorable economic and political climate had weighed on its profitability.The online retail specialist, positioned in the IT and high-tech sectors, reported a net loss of 7.3 million euros in the six months to the end of September, compared with -3.7 million euros a year earlier.EBITDA also showed a loss, at -2.5 million euros for the first half of 2024-2025, compared with a positive figure of 2.9 million euros for the first half of 2023-2024.Half-year sales came to 243.7 million euros, down 8.7% on the first half of 2023-2024 and 9.1% on a like-for-like basis (excluding the impact of Rue du Commerce, which has been consolidated since July 2024).In a note, analysts at TP ICAP Midcap refer to 'heavy losses, as expected', recalling that they were expecting 'significantly deteriorated' half-year results for their part.'We'll still have to be patient to see a clearing', warns the brokerage firm.In its press release, LDLC points out that its business is traditionally stronger in the second half of the year, which should enable it, in addition to the measures implemented to control operating costs, to improve its profitability in the second half.Following this publication, the LDLC share was down 0.6% on the Paris Bourse at the end of the morning.Copyright (c) 2024 CercleFinance.com. All rights reserved.
Dec 06, 2024 | www.marketscreener.com
NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024
– Met primary endpoint with LDL-C mean reduction versus placebo of 36.3% at day 84 and 41.5% at day 365 – – Lp(a) mean reduction versus placebo of 45.9% at day 84 and 54.3% at day 365 – – Total LDL-P mean reduction versus placebo of 52.5% at day 180, with small LDL-P reduction of 102.4% – – Safety results comparable to placebo – NAARDEN, the Netherlands and MIAMI, Nov. 18, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced additional results from the Company's Phase 3 BROOKLYN clinical trial (NCT05425745) evaluating obicetrapib in adult patients with heterozygous familial hypercholesterolemia (“HeFH”), whose LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy.
Nov 18, 2024 | www.globenewswire.com
Obicetrapib Positions NewAmsterdam Pharma For Significant Market Growth In Cardiovascular Therapies
NewAmsterdam Pharma's Obicetrapib, a CETP inhibitor, shows promise in reducing LDL-C, addressing unmet cardiovascular needs, and has favorable Phase 3 trial results. Obicetrapib's potential regulatory filing by 2025 and its competitive edge over similar drugs position NAMS for significant market share in cardiovascular therapies. This drug significantly reduced LDL-C in Phase 3 trials, outperforming similar therapies. It also seems highly effective at lowering Lp(a).
Oct 04, 2024 | seekingalpha.com
New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries
– Targeted Campaign Reaches Patients at Risk for Heart Attack or Heart Procedures Because of High LDL Cholesterol (LDL-C) –
Jul 16, 2024 | www.globenewswire.com
Clearlake Capital-Backed Unifrax Completes Acquisition of Lydall
TONAWANDA, N.Y & MANCHESTER, Conn.--(BUSINESS WIRE)--Unifrax, a leading global provider of high-performance specialty materials focused on thermal management, specialty filtration, battery materials, emission control and fire protection applications backed by Clearlake Capital Group, L.P. (together with its affiliates, “Clearlake”), today announced the completion of its previously announced acquisition of Lydall, Inc. (NYSE: LDL, “Lydall” or the “Company”), a leader in the design and production
Oct 08, 2021 | www.businesswire.com
Unifrax Announces Pricing of Notes Offering
BUFFALO, N.Y., Sept. 16, 2021 /PRNewswire/ -- ASP Unifrax Holdings, Inc. ("Unifrax") announced that it has priced an offering (the "Offering") of $800,000,000 aggregate principal amount of its 5.250% Senior Secured Notes due 2028 (the "Secured Notes") and $400,000,000 aggregate principal amount of its 7.500% Senior Notes due 2029 (the "Unsecured Notes" and, together with the Secured Notes, the "Notes") in a private placement transaction, exempt from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act").
Sep 16, 2021 | www.prnewswire.com

Lydall's Email Address Formats

Lydall uses at least 1 format(s):

Lydall Email Formats	Example	Percentage
FLast@lydall.com	JDoe@lydall.com	92%
First.Last@lydall.com	John.Doe@lydall.com	6%
LFirst@lydall.com	DJohn@lydall.com	1%
LastF@lydall.com	DoeJ@lydall.com	1%

Frequently Asked Questions

Where is Lydall's headquarters located?

Lydall's main headquarters is located at 1 Colonial Rd, Manchester, Connecticut 06042, US. The company has employees across 3 continents, including North AmericaEuropeAsia.

What is Lydall's phone number?

You can contact Lydall's main corporate office by phone at

+1-860-646-****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Lydall's stock symbol?

Lydall is a publicly traded company; the company's stock symbol is LDL.

What is Lydall's official website and social media links?

Lydall's official website is lydall.com and has social profiles on LinkedIn.

How much revenue does Lydall generate?

As of June 2025, Lydall's annual revenue reached $764M.

What is Lydall's NAICS code?

Lydall's NAICS code is 444110 - Home Centers.

How many employees does Lydall have currently?

As of June 2025, Lydall has approximately 1K employees across 3 continents, including North AmericaEuropeAsia. Key team members include Chief Information Officer: J. T.Chief Audit Executive: G. D.Vice President Human Resources: K. T.. Explore Lydall's employee directory with LeadIQ.

What industry does Lydall belong to?

Lydall operates in the Industrial Machinery Manufacturing industry.

What technology does Lydall use?

Lydall's tech stack includes Microsoft SharePointOraclePure StorageCovisintWindows ServerMicrosoft AzureVMwareApache HTTP Server.

What is Lydall's email format?

Lydall's email format typically follows the pattern of . Find more Lydall email formats with LeadIQ.

Insights

Similar companies to Lydall

Ingersoll Rand

Aearo Technologies

Lydall Tech Stack

Media & News

Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

LDLC: heavier first-half losses

NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024

Obicetrapib Positions NewAmsterdam Pharma For Significant Market Growth In Cardiovascular Therapies

New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries

Clearlake Capital-Backed Unifrax Completes Acquisition of Lydall

Unifrax Announces Pricing of Notes Offering

Lydall's Email Address Formats

Frequently Asked Questions

Where is Lydall's headquarters located?

What is Lydall's phone number?

What is Lydall's stock symbol?

What is Lydall's official website and social media links?

How much revenue does Lydall generate?

What is Lydall's NAICS code?

How many employees does Lydall have currently?

What industry does Lydall belong to?

What technology does Lydall use?

What is Lydall's email format?

Lydall

Company Overview

Media & News

Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

LDLC: heavier first-half losses

NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?